Market Place
Sourcing Support
Lutris Completes Enrollment In Ph 2 Trial of EGFRI Acneiform Rash
15 Oct 2024 //
PR NEWSWIRE
Tris Pharma captures FDA nod for non-stimulant ADHD treatment Onyda XR
30 May 2024 //
FIERCE PHARMA
Lutris Pharma Appoints Moshe "Mori" Arkin to Its Board of Directors
01 Apr 2024 //
PR NEWSWIRE
Lutris Pharma Receives FDA Orphan Drug Designation for LUT014
28 Feb 2024 //
PR NEWSWIRE
Lutris Announces Publication of Positive Data From Phase 1/2 Trial of LUT014
21 Feb 2024 //
PR NEWSWIRE
Lutris Presents Data From a Analysis of Skin Toxicity From EGFR Inhibitors
17 Mar 2023 //
PR NEWSWIRE
Lutris Pharma to Present at Annual European Life Sciences CEO Forum in March
16 Feb 2023 //
PR NEWSWIRE
Lutris` Founder and Chairman of the Board Receives $5.0 Million Grant from CIRM
24 Oct 2022 //
PRNEWSWIRE
Lutris Pharma Receives NoA for Key U.S. Patent Covering Lead Compound, LUT014
11 Jul 2022 //
PRNEWSWIRE
Lutris Pharma Appoints Antoni Ribas as Chairman of Board of Directors
10 May 2022 //
PRNEWSWIRE
Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014
05 Oct 2021 //
PRNEWSWIRE
Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014
03 Aug 2021 //
PRNEWSWIRE
Lutris Pharma Appoints Life Science Executive, Jack Weinstein
29 Jun 2021 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.